147 related articles for article (PubMed ID: 33639073)
81. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
82. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.
Grossmann V; Tiacci E; Holmes AB; Kohlmann A; Martelli MP; Kern W; Spanhol-Rosseto A; Klein HU; Dugas M; Schindela S; Trifonov V; Schnittger S; Haferlach C; Bassan R; Wells VA; Spinelli O; Chan J; Rossi R; Baldoni S; De Carolis L; Goetze K; Serve H; Peceny R; Kreuzer KA; Oruzio D; Specchia G; Di Raimondo F; Fabbiano F; Sborgia M; Liso A; Farinelli L; Rambaldi A; Pasqualucci L; Rabadan R; Haferlach T; Falini B
Blood; 2011 Dec; 118(23):6153-63. PubMed ID: 22012066
[TBL] [Abstract][Full Text] [Related]
83. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.
Hou HA; Kuo YY; Liu CY; Chou WC; Lee MC; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Blood; 2012 Jan; 119(2):559-68. PubMed ID: 22077061
[TBL] [Abstract][Full Text] [Related]
84. DOT1L inhibitors block abnormal self-renewal induced by cohesin loss.
Heimbruch KE; Fisher JB; Stelloh CT; Phillips E; Reimer MH; Wargolet AJ; Meyer AE; Pulakanti K; Viny AD; Loppnow JJ; Levine RL; Pulikkan JA; Zhu N; Rao S
Sci Rep; 2021 Mar; 11(1):7288. PubMed ID: 33790356
[TBL] [Abstract][Full Text] [Related]
85. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
86. RAD21 mutations cause a human cohesinopathy.
Deardorff MA; Wilde JJ; Albrecht M; Dickinson E; Tennstedt S; Braunholz D; Mönnich M; Yan Y; Xu W; Gil-Rodríguez MC; Clark D; Hakonarson H; Halbach S; Michelis LD; Rampuria A; Rossier E; Spranger S; Van Maldergem L; Lynch SA; Gillessen-Kaesbach G; Lüdecke HJ; Ramsay RG; McKay MJ; Krantz ID; Xu H; Horsfield JA; Kaiser FJ
Am J Hum Genet; 2012 Jun; 90(6):1014-27. PubMed ID: 22633399
[TBL] [Abstract][Full Text] [Related]
87. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
[TBL] [Abstract][Full Text] [Related]
88. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Lindsley RC; Mar BG; Mazzola E; Grauman PV; Shareef S; Allen SL; Pigneux A; Wetzler M; Stuart RK; Erba HP; Damon LE; Powell BL; Lindeman N; Steensma DP; Wadleigh M; DeAngelo DJ; Neuberg D; Stone RM; Ebert BL
Blood; 2015 Feb; 125(9):1367-76. PubMed ID: 25550361
[TBL] [Abstract][Full Text] [Related]
89. [Identification of novel pathogenic gene mutations in pediatric acute myeloid leukemia by whole-exome resequencing].
Shiba N
Rinsho Ketsueki; 2015 Dec; 56(12):2419-25. PubMed ID: 26725349
[TBL] [Abstract][Full Text] [Related]
90. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
91. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.
Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Pratcorona M; Abbas S; Kuipers JE; van Galen JF; Beverloo HB; Sonneveld E; Kaspers GJ; Trka J; Baruchel A; Zimmermann M; Creutzig U; Reinhardt D; Pieters R; Valk PJ; Zwaan CM
Blood; 2011 Sep; 118(13):3645-56. PubMed ID: 21813447
[TBL] [Abstract][Full Text] [Related]
92. Cohesin subunits, STAG1 and STAG2, and cohesin regulatory factor, PDS5b, in oral squamous cells carcinomas.
França JA; Diniz MG; Bernardes VF; Costa-Silva RC; Souza RP; Gomez RS; Gomes CC
J Oral Pathol Med; 2017 Mar; 46(3):188-193. PubMed ID: 27341316
[TBL] [Abstract][Full Text] [Related]
93. Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.
Majeti R
Best Pract Res Clin Haematol; 2014; 27(3-4):229-34. PubMed ID: 25455271
[TBL] [Abstract][Full Text] [Related]
94. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
95. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
[TBL] [Abstract][Full Text] [Related]
96. RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia.
Yang X; Qian J; Sun A; Lin J; Xiao G; Yin J; Chen S; Wu D
Clin Biochem; 2013 May; 46(7-8):579-83. PubMed ID: 23313659
[TBL] [Abstract][Full Text] [Related]
97. Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
Martelli MP; Sportoletti P; Tiacci E; Martelli MF; Falini B
Blood Rev; 2013 Jan; 27(1):13-22. PubMed ID: 23261068
[TBL] [Abstract][Full Text] [Related]
98. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
[TBL] [Abstract][Full Text] [Related]
99. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
Bouvier A; Hamel JF; Delaunay J; Delabesse E; Dumas PY; Ledoux MP; Peterlin P; Luquet I; Roth Guepin G; Bulabois CE; Gallego Hernanz MP; Guillerm G; Guieze R; Hicheri Y; Simand C; Himberlin C; Hunault-Berger M; Bernard M; Jourdan E; Caillot D; Dorvaux V; Tavernier E; Daguindau E; Banos A; Ojeda-Uribe M; Gyan E; Alexis M; Marolleau JP; Turlure P; Bouscary D; Humbrecht C; Zerazhi H; Béné MC; Pigneux A; Carre M; Ifrah N; Blanchet O; Vey N; Récher C; Cornillet-Lefèbvre P;
Eur J Haematol; 2021 Jul; 107(1):111-121. PubMed ID: 33765335
[TBL] [Abstract][Full Text] [Related]
100. Imbalance of SMC1 and SMC3 cohesins causes specific and distinct effects.
Laugsch M; Seebach J; Schnittler H; Jessberger R
PLoS One; 2013; 8(6):e65149. PubMed ID: 23776448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
